MedKoo Biosciences

About us  |  Services  |  Products  |  News  |  Careers  |  Contact us

 

 

 


 

Back to products

 

 Browse products

Approved anticancer agents

Anticancer agents in trials

Anticancer agents in preclinical trials

Anticancer molecular libraries

 


Other drug agents

Drug intermediates

Bio-reagents and biochemicals

 

 

 

 

 

 

 

 

MedKoo product information:

 

   Ilorasertib

     

Description of Ilorasertib (ABT-348)Ilorasertib, also know as ABT-348,  is a novel, potent and orally bioavailable inhibitor of the Aurora kinases as well as the VEGF and PDGF families of receptor tyrosine kinases and is currently in Phase I clinical trials. ABT-348 has nanomolar potency (IC50) for inhibiting binding and cellular auto-phosphorylation of Aurora B (7 and 13 nM), C (1 and 13 nM) and A (120 and 189 nM).   Based upon its unique spectrum of activity, ABT 348 was evaluated and found effective in representative solid tumor (HT1080 and MiaPaCa, tumor stasis) and hematological malignancy (RS4;11, regression) xenografts. These results provide the rationale for clinical assessment of ABT-348 as a therapeutic agent in the treatment of cancer.

 

Current developer: Abbott Laboratories, Inc.

  

MedKoo Cat#: 204140

Name:  Ilorasertib

CAS#:   1227939-82-3

  

Synonym:  ABT-348; Abbott 968660; Ilorasertib

  

IUPAC/Chemical name: 

1-(4-(4-amino-7-(1-(2-hydroxyethyl)-1H-pyrazol-4-yl)thieno[3,2-c]pyridin-3-yl)phenyl)-3-(3-fluorophenyl)urea  

  

Chemical structure

Theoretical analysis

 

 

 

MedKoo Cat#: 204140
Name:  Ilorasertib
CAS#:   1227939-82-3

Chemical Formula: C25H21FN6O2S
Exact Mass: 488.14307
Molecular Weight: 488.54
Elemental Analysis: C, 61.46; H, 4.33; F, 3.89; N, 17.20; O, 6.55; S, 6.56

 

  

Availability and price:

  

Ilorasertib (ABT-348) is available through custom synthesis.  Minimum order is requested.

  

To inquire quotation and lead time or to ask questions, please send email to sales@medkoo.com to describe your needs. A representative will respond your email shortly. We offer big discount for orders of bulk quantities.

  

 

Highlights of recent research using this agent

  

 

 

References

1: Glaser KB, Li J, Marcotte PA, Magoc TJ, Guo J, Reuter DR, Tapang P, Wei RQ,
Pease LJ, Bui MH, Chen Z, Frey RR, Johnson EF, Osterling DJ, Olson AM, Bouska JJ,
Luo Y, Curtin ML, Donawho CK, Michaelides MR, Tse C, Davidsen SK, Albert DH.
Preclinical characterization of ABT-348, a kinase inhibitor targeting the Aurora,
VEGFR/PDGFR, and SRC kinase families. J Pharmacol Exp Ther. 2012 Aug 30. [Epub
ahead of print] PubMed PMID: 22935731.


2: Curtin ML, Heyman HR, Frey RR, Marcotte PA, Glaser KB, Jankowski JR, Magoc TJ,
Albert DH, Olson AM, Reuter DR, Bouska JJ, Montgomery DA, Palma JP, Donawho CK,
Stewart KD, Tse C, Michaelides MR. Pyrazole diaminopyrimidines as dual inhibitors
of KDR and Aurora B kinases. Bioorg Med Chem Lett. 2012 Jul 15;22(14):4750-5.
Epub 2012 May 26. PubMed PMID: 22695126.


3: Curtin ML, Frey RR, Heyman HR, Soni NB, Marcotte PA, Pease LJ, Glaser KB,
Magoc TJ, Tapang P, Albert DH, Osterling DJ, Olson AM, Bouska JJ, Guan Z,
Preusser LC, Polakowski JS, Stewart KD, Tse C, Davidsen SK, Michaelides MR.
Thienopyridine ureas as dual inhibitors of the VEGF and Aurora kinase families.
Bioorg Med Chem Lett. 2012 May 1;22(9):3208-12. doi: 10.1016/j.bmcl.2012.03.035.
Epub 2012 Mar 14. PubMed PMID: 22465635.
  

 

 

Contact MedKoo:

Email: sales@medkoo.com

 

(Keyword; CAS#; MedKoo Cat#)

 

 

 

 

 

 

 

About us  |  Services  |  Products  |  News  |  Careers  |  Contact us

MedKoo Biosciences. All Rights Reserved